1 Market Overview

1.1 Product Overview and Scope of Neurodegenerative Disorder Therapeutics

1.2 Classification of Neurodegenerative Disorder Therapeutics by Type

1.2.1 Overview: Global Neurodegenerative Disorder Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type in 2020

1.2.3 Immunomodulators

1.2.4 Interferons

1.2.5 Decarboxylase Inhibitors

1.2.6 Dopamine Agonists

1.2.7 Others

1.3 Global Neurodegenerative Disorder Therapeutics Market by Application

1.3.1 Overview: Global Neurodegenerative Disorder Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Multiple Sclerosis

1.3.3 Parkinson'S Disease

1.3.4 Alzheimer'S Disease

1.3.5 Spinal Muscular Atrophy

1.3.6 Huntington Disease

1.3.7 Other Neurodegenerative Disorders

1.4 Global Neurodegenerative Disorder Therapeutics Market Size & Forecast

1.5 Global Neurodegenerative Disorder Therapeutics Market Size and Forecast by Region

1.5.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Neurodegenerative Disorder Therapeutics Market Size by Region, (2016-2021)

1.5.3 North America Neurodegenerative Disorder Therapeutics Market Size and Prospect (2016-2026)

1.5.4 Europe Neurodegenerative Disorder Therapeutics Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size and Prospect (2016-2026)

1.5.6 South America Neurodegenerative Disorder Therapeutics Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Neurodegenerative Disorder Therapeutics Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Neurodegenerative Disorder Therapeutics Market Drivers

1.6.2 Neurodegenerative Disorder Therapeutics Market Restraints

1.6.3 Neurodegenerative Disorder Therapeutics Trends Analysis

2 Company Profiles

2.1 Biogen, Inc.

2.1.1 Biogen, Inc. Details

2.1.2 Biogen, Inc. Major Business

2.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

2.1.4 Biogen, Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Biogen, Inc. Recent Developments and Future Plans

2.2 Pfizer, Inc.

2.2.1 Pfizer, Inc. Details

2.2.2 Pfizer, Inc. Major Business

2.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

2.2.4 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Pfizer, Inc. Recent Developments and Future Plans

2.3 Novartis AG

2.3.1 Novartis AG Details

2.3.2 Novartis AG Major Business

2.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Product and Solutions

2.3.4 Novartis AG Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Novartis AG Recent Developments and Future Plans

2.4 Sanofi S.A.

2.4.1 Sanofi S.A. Details

2.4.2 Sanofi S.A. Major Business

2.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product and Solutions

2.4.4 Sanofi S.A. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Sanofi S.A. Recent Developments and Future Plans

2.5 Teva Pharmaceutical Industries Ltd.

2.5.1 Teva Pharmaceutical Industries Ltd. Details

2.5.2 Teva Pharmaceutical Industries Ltd. Major Business

2.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product and Solutions

2.5.4 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans

2.6 UCB S.A.

2.6.1 UCB S.A. Details

2.6.2 UCB S.A. Major Business

2.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Product and Solutions

2.6.4 UCB S.A. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 UCB S.A. Recent Developments and Future Plans

2.7 F. Hoffmann- La Roche Ltd.

2.7.1 F. Hoffmann- La Roche Ltd. Details

2.7.2 F. Hoffmann- La Roche Ltd. Major Business

2.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product and Solutions

2.7.4 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 F. Hoffmann- La Roche Ltd. Recent Developments and Future Plans

2.8 H. Lundbeck

2.8.1 H. Lundbeck Details

2.8.2 H. Lundbeck Major Business

2.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Product and Solutions

2.8.4 H. Lundbeck Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 H. Lundbeck Recent Developments and Future Plans

2.9 Merck KGaA

2.9.1 Merck KGaA Details

2.9.2 Merck KGaA Major Business

2.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Product and Solutions

2.9.4 Merck KGaA Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Merck KGaA Recent Developments and Future Plans

2.10 GlaxoSmithKline PLC

2.10.1 GlaxoSmithKline PLC Details

2.10.2 GlaxoSmithKline PLC Major Business

2.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product and Solutions

2.10.4 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 GlaxoSmithKline PLC Recent Developments and Future Plans

2.11 AbbVie Inc.

2.11.1 AbbVie Inc. Details

2.11.2 AbbVie Inc. Major Business

2.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

2.11.4 AbbVie Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 AbbVie Inc. Recent Developments and Future Plans

2.12 Bristol Myers Squibb Company

2.12.1 Bristol Myers Squibb Company Details

2.12.2 Bristol Myers Squibb Company Major Business

2.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product and Solutions

2.12.4 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Bristol Myers Squibb Company Recent Developments and Future Plans

2.13 Boehringer Ingeiheim International GmbH

2.13.1 Boehringer Ingeiheim International GmbH Details

2.13.2 Boehringer Ingeiheim International GmbH Major Business

2.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product and Solutions

2.13.4 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Boehringer Ingeiheim International GmbH Recent Developments and Future Plans

2.14 Bayer AG

2.14.1 Bayer AG Details

2.14.2 Bayer AG Major Business

2.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Product and Solutions

2.14.4 Bayer AG Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Bayer AG Recent Developments and Future Plans

2.15 Eisai Co., Ltd

2.15.1 Eisai Co., Ltd Details

2.15.2 Eisai Co., Ltd Major Business

2.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product and Solutions

2.15.4 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Eisai Co., Ltd Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Neurodegenerative Disorder Therapeutics Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Neurodegenerative Disorder Therapeutics Players Market Share

3.2.2 Top 10 Neurodegenerative Disorder Therapeutics Players Market Share

3.2.3 Market Competition Trend

3.3 Neurodegenerative Disorder Therapeutics Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Neurodegenerative Disorder Therapeutics Revenue and Market Share by Type (2016-2021)

4.2 Global Neurodegenerative Disorder Therapeutics Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2016-2021)

5.2 Neurodegenerative Disorder Therapeutics Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2026)

6.2 North America Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2026)

6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country

6.3.1 North America Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2026)

6.3.2 United States Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

6.3.3 Canada Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

6.3.4 Mexico Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2026)

7.2 Europe Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2026)

7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country

7.3.1 Europe Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2026)

7.3.2 Germany Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

7.3.3 France Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

7.3.5 Russia Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

7.3.6 Italy Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2026)

8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2026)

8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region

8.3.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Region (2016-2026)

8.3.2 China Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8.3.3 Japan Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8.3.4 South Korea Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8.3.5 India Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

8.3.7 Australia Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2026)

9.2 South America Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2026)

9.3 South America Neurodegenerative Disorder Therapeutics Market Size by Country

9.3.1 South America Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2026)

9.3.2 Brazil Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

9.3.3 Argentina Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2026)

10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2026)

10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country

10.3.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2026)

10.3.2 Turkey Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

10.3.4 UAE Neurodegenerative Disorder Therapeutics Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Neurodegenerative Disorder Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Neurodegenerative Disorder Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Neurodegenerative Disorder Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Neurodegenerative Disorder Therapeutics Revenue (USD Million) by Region (2016-2021)

Table 5. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2021-2026)

Table 6. Biogen, Inc. Corporate Information, Head Office, and Major Competitors

Table 7. Biogen, Inc. Major Business

Table 8. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 9. Biogen, Inc. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer, Inc. Major Business

Table 12. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 13. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Novartis AG Corporate Information, Head Office, and Major Competitors

Table 15. Novartis AG Major Business

Table 16. Novartis AG Neurodegenerative Disorder Therapeutics Product and Solutions

Table 17. Novartis AG Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Sanofi S.A. Corporate Information, Head Office, and Major Competitors

Table 19. Sanofi S.A. Major Business

Table 20. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 21. Sanofi S.A. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Teva Pharmaceutical Industries Ltd. Corporate Information, Head Office, and Major Competitors

Table 23. Teva Pharmaceutical Industries Ltd. Major Business

Table 24. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 25. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. UCB S.A. Corporate Information, Head Office, and Major Competitors

Table 27. UCB S.A. Major Business

Table 28. UCB S.A. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 29. UCB S.A. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. F. Hoffmann- La Roche Ltd. Corporate Information, Head Office, and Major Competitors

Table 31. F. Hoffmann- La Roche Ltd. Major Business

Table 32. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 33. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. H. Lundbeck Corporate Information, Head Office, and Major Competitors

Table 35. H. Lundbeck Major Business

Table 36. H. Lundbeck Neurodegenerative Disorder Therapeutics Product and Solutions

Table 37. H. Lundbeck Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Merck KGaA Corporate Information, Head Office, and Major Competitors

Table 39. Merck KGaA Major Business

Table 40. Merck KGaA Neurodegenerative Disorder Therapeutics Product and Solutions

Table 41. Merck KGaA Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. GlaxoSmithKline PLC Corporate Information, Head Office, and Major Competitors

Table 43. GlaxoSmithKline PLC Major Business

Table 44. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product and Solutions

Table 45. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. AbbVie Inc. Corporate Information, Head Office, and Major Competitors

Table 47. AbbVie Inc. Major Business

Table 48. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product and Solutions

Table 49. AbbVie Inc. Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Bristol Myers Squibb Company Corporate Information, Head Office, and Major Competitors

Table 51. Bristol Myers Squibb Company Major Business

Table 52. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product and Solutions

Table 53. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Boehringer Ingeiheim International GmbH Corporate Information, Head Office, and Major Competitors

Table 55. Boehringer Ingeiheim International GmbH Major Business

Table 56. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product and Solutions

Table 57. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Bayer AG Corporate Information, Head Office, and Major Competitors

Table 59. Bayer AG Major Business

Table 60. Bayer AG Neurodegenerative Disorder Therapeutics Product and Solutions

Table 61. Bayer AG Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Eisai Co., Ltd Corporate Information, Head Office, and Major Competitors

Table 63. Eisai Co., Ltd Major Business

Table 64. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product and Solutions

Table 65. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Global Neurodegenerative Disorder Therapeutics Revenue (USD Million) by Players (2019-2021)

Table 67. Global Neurodegenerative Disorder Therapeutics Revenue Share by Players (2019-2021)

Table 68. Breakdown of Neurodegenerative Disorder Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Neurodegenerative Disorder Therapeutics Players Head Office, Products and Services Provided

Table 70. Neurodegenerative Disorder Therapeutics Mergers & Acquisitions in the Past Five Years

Table 71. Neurodegenerative Disorder Therapeutics New Entrants and Expansion Plans

Table 72. Global Neurodegenerative Disorder Therapeutics Revenue (USD Million) by Type (2016-2021)

Table 73. Global Neurodegenerative Disorder Therapeutics Revenue Share by Type (2016-2021)

Table 74. Global Neurodegenerative Disorder Therapeutics Revenue Forecast by Type (2021-2026)

Table 75. Global Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021)

Table 76. Global Neurodegenerative Disorder Therapeutics Revenue Forecast by Application (2021-2026)

Table 77. North America Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 78. North America Neurodegenerative Disorder Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 79. North America Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 80. North America Neurodegenerative Disorder Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 81. North America Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 82. North America Neurodegenerative Disorder Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 83. Europe Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 84. Europe Neurodegenerative Disorder Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 85. Europe Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 86. Europe Neurodegenerative Disorder Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 87. Europe Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 88. Europe Neurodegenerative Disorder Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 89. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 90. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 91. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 92. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 93. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Region (2016-2021) & (USD Million)

Table 94. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue by Region (2021-2026) & (USD Million)

Table 95. South America Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 96. South America Neurodegenerative Disorder Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 97. South America Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 98. South America Neurodegenerative Disorder Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 99. South America Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 100. South America Neurodegenerative Disorder Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 101. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 102. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 103. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 104. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 105. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 106. Middle East & Africa Neurodegenerative Disorder Therapeutics Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Neurodegenerative Disorder Therapeutics Picture

Figure 2. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type in 2020

Figure 3. Immunomodulators

Figure 4. Interferons

Figure 5. Decarboxylase Inhibitors

Figure 6. Dopamine Agonists

Figure 7. Others

Figure 8. Neurodegenerative Disorder Therapeutics Revenue Market Share by Application in 2020

Figure 9. Multiple Sclerosis Picture

Figure 10. Parkinson'S Disease Picture

Figure 11. Alzheimer'S Disease Picture

Figure 12. Spinal Muscular Atrophy Picture

Figure 13. Huntington Disease Picture

Figure 14. Other Neurodegenerative Disorders Picture

Figure 15. Global Neurodegenerative Disorder Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 16. Global Neurodegenerative Disorder Therapeutics Revenue and Forecast (2016-2026) & (USD Million)

Figure 17. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2016-2026)

Figure 18. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Region in 2020

Figure 19. North America Neurodegenerative Disorder Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Europe Neurodegenerative Disorder Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. South America Neurodegenerative Disorder Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. Middle East and Africa Neurodegenerative Disorder Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 24. Neurodegenerative Disorder Therapeutics Market Drivers

Figure 25. Neurodegenerative Disorder Therapeutics Market Restraints

Figure 26. Neurodegenerative Disorder Therapeutics Market Trends

Figure 27. Biogen, Inc. Recent Developments and Future Plans

Figure 28. Pfizer, Inc. Recent Developments and Future Plans

Figure 29. Novartis AG Recent Developments and Future Plans

Figure 30. Sanofi S.A. Recent Developments and Future Plans

Figure 31. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans

Figure 32. UCB S.A. Recent Developments and Future Plans

Figure 33. F. Hoffmann- La Roche Ltd. Recent Developments and Future Plans

Figure 34. H. Lundbeck Recent Developments and Future Plans

Figure 35. Merck KGaA Recent Developments and Future Plans

Figure 36. GlaxoSmithKline PLC Recent Developments and Future Plans

Figure 37. AbbVie Inc. Recent Developments and Future Plans

Figure 38. Bristol Myers Squibb Company Recent Developments and Future Plans

Figure 39. Boehringer Ingeiheim International GmbH Recent Developments and Future Plans

Figure 40. Bayer AG Recent Developments and Future Plans

Figure 41. Eisai Co., Ltd Recent Developments and Future Plans

Figure 42. Global Neurodegenerative Disorder Therapeutics Revenue Share by Players in 2020

Figure 43. Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 44. Global Top 3 Players Neurodegenerative Disorder Therapeutics Revenue Market Share in 2020

Figure 45. Global Top 10 Players Neurodegenerative Disorder Therapeutics Revenue Market Share in 2020

Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 47. Global Neurodegenerative Disorder Therapeutics Revenue Share by Type in 2020

Figure 48. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Type (2021-2026)

Figure 49. Global Neurodegenerative Disorder Therapeutics Revenue Share by Application in 2020

Figure 50. Global Neurodegenerative Disorder Therapeutics Market Share Forecast by Application (2021-2026)

Figure 51. North America Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2016-2026)

Figure 52. North America Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2016-2026)

Figure 53. North America Neurodegenerative Disorder Therapeutics Revenue Market Share by Country (2016-2026)

Figure 54. United States Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Canada Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Mexico Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Europe Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2016-2026)

Figure 58. Europe Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2016-2026)

Figure 59. Europe Neurodegenerative Disorder Therapeutics Revenue Market Share by Country (2016-2026)

Figure 60. Germany Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. France Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. United Kingdom Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Russia Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Italy Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Asia-Pacific Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2016-2026)

Figure 66. Asia-Pacific Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2016-2026)

Figure 67. Asia-Pacific Neurodegenerative Disorder Therapeutics Revenue Market Share by Region (2016-2026)

Figure 68. China Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Japan Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. South Korea Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. India Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. Southeast Asia Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Australia Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. South America Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2016-2026)

Figure 75. South America Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2016-2026)

Figure 76. South America Neurodegenerative Disorder Therapeutics Revenue Market Share by Country (2016-2026)

Figure 77. Brazil Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. Argentina Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Market Share by Type (2016-2026)

Figure 80. Middle East and Africa Neurodegenerative Disorder Therapeutics Sales Market Share by Application (2016-2026)

Figure 81. Middle East and Africa Neurodegenerative Disorder Therapeutics Revenue Market Share by Country (2016-2026)

Figure 82. Turkey Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 83. Saudi Arabia Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 84. UAE Neurodegenerative Disorder Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 85. Methodology

Figure 86. Research Process and Data Source